Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MPT-062
- Development stage
- Preclinical
- Lead developer
- Matchpoint Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MPT-062 is an oral, first-in-class small molecule T-cell modulator being developed by Matchpoint Therapeutics. It is designed to selectively address the overactivation of T cells, which is a key driver of autoimmune and inflammatory diseases. MPT-062 utilizes a precision covalent chemistry mechanism to target historically hard-to-drug proteins involved in dysregulated T-cell activation. The drug is currently in preclinical development, with clinical trials expected to begin in 2027.
Beyond the preview
Go deeper on MPT-062.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MPT-062.